T
Tafalgie Therapeutics
Biotech & Life Sciences · Marseille, France · Founded 2020
Next-generation pain management treatments derived from an endogenous secreted protein capable of modulating pain signals MoreLess
Tafalgie Therapeutics is a French biopharmaceutical startup that specializes in the development of non-opioid drugs for the treatment of chronic, severe, or persistent pain. The company is a spin-off from the French National Centre for Scientific Research (CNRS) and Aix-Marseille University (AMU). Their primary focus is on creating a new scientific approach for next-generation treatments, which are based on an innovative mechanism of action derived from a protein capable of modulating pain signals. This is a significant breakthrough in the medical field, especially considering the current opioid crisis.
Tafalgie Therapeutics serves a broad range of clients, including patients suffering from acute severe pain and chronic refractory pain. The company operates in the global pharmaceutical market, which is expected to reach $100 billion by 2030. Their business model revolves around the research, development, and commercialization of their unique, non-addictive pain relief drugs.
The company generates revenue through the sale of these drugs, which are designed to provide high-efficacy, high-tolerability, and non-addictive solutions for pain management. They are also dedicated to the prevention and treatment of chronic refractory pain, a condition that is often inadequately treated.
In summary, Tafalgie Therapeutics is a promising startup in the pharmaceutical industry, with a unique approach to pain management that could revolutionize the treatment of chronic and severe pain.
Keywords: Tafalgie Therapeutics, non-opioid drugs, chronic pain, severe pain, persistent pain, biopharmaceutical research, pain management, CNRS, AMU, pharmaceutical market.
Company overview
Tafalgie Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Marseille, France
- Employees
- 29
- Open positions
- None listed
- Dealroom signal
- 88.0
Valuation & funding
Tafalgie Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Sep 2025 | $13M | $53M | Bpifrance | ↗ |
| GRANT✓Other financing | Jun 2023 | $2.5M | — | European Innovation Council | — |
| SUPPORT PROGRAM✓Other financing | Apr 2021 | $0 | — | Incubateur Impulse | ↗ |
| ANGEL✓Equity / VC | Feb 2021 | $2.8M | $11M | Laurent Labatut · Eric Schettini | ↗ |
| SPINOUT✓Other financing | Oct 2020 | — | — | CNRS Innovation · French National Centre for Scientific Research - CNRS · SATT Sud-Est | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 29 |
| 2025 | 23 |
| 2024 | 15 |
| 2023 | 12 |
Growth signals
Tafalgie Therapeutics website traffic
Latest recorded traffic for Tafalgie Therapeutics is 1.6K monthly website visits, up 63.3% over the last three months. Tafalgie Therapeutics's team grew 26.1% over the past year.
Comparisons
Tafalgie Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Tafalgie Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Tafalgie Therapeutics has talent and traffic
team presence
In the news
Latest news about Tafalgie Therapeutics
Recent press, funding announcements, and product moves mentioning Tafalgie Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Tafalgie Therapeutics
An AI-synthesized read of the highest-engagement posts about Tafalgie Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tafalgie Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.